Thirty patients with previously untreated and measurable or evaluable advanced sofr tissue sarcoma entered this phase II study. Median age was 53 years (range: 24–71 years). Starting dose of Epirubicin was 100 mg/m2IV bolus on day I combined with Ifosfamide, 2.5 g/m2, as a 6-hr IV infusion on day I and day 2 with uroprotection with Uromitexan, 1.6 g/m2, on day 1 and day 2. This schedule was repeated every 3 weeks. In case of minimal myelosuppression, the dose of Epirubicin was increased by 10 mg/m2up to 130 mg/m2. Ifosfamide dosage was not increased. Mean cumulative dose of Epirubicin received was 477±272 mg/m2(range: 200–1200 mg/m2). Of 27 evaluable patients (WHO criteria), 13 had a partial response (48%), 4 showed no change (15%), and 10 had progressive disease (37%). Median time to progression was 27 weeks. Of 27 patients evaluable for toxicity. hemato-logical toxicity at day 21 was mild. Nonhematological toxicities consisted of nausea and vomiting in 82% of patients (WHO grade 3–4 = 19%). stomatitis in 44.5% (WHO grade 3 = 7.5%), and alopecia in 96% (WHO grade 2–3 = 89%). Appearance of cardiac dysfunction without heart failure during the treatment led to discontinuation of this chemotherapy in 3 patients. The results of this study show that the combination of Epirubicin and Ifosfamide is effective in advanced soft tissue sarcoma with an acceptable toxicity. However, we cannot conclude from this trial whether combination Epirubicin and Ifosfamide is superior to Epirubicin alone.